Key Takeaways:
- Strategic Shift: Company launching 2030 growth strategy focused on premiumization and omnichannel demand generation.
- Price Projection: Based on current execution, CL stock could reach $114 by December 2028.
- Potential Gains: This target implies a total return of 19% from the current price of $95.51.
- Annual Return: Investors could see roughly 6% growth over the next 2.8 years.
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)>>>
Colgate-Palmolive (CL) delivered stronger-than-expected Q4 2025 results despite significant headwinds, including sluggish category growth, raw-material inflation, and tariff pressures.
The company achieved organic sales growth across all four categories in Q4 with sequential improvement in every division except North America.
Chairman, President, and Chief Executive Officer Noel Wallace emphasized the resilience of their operating model, which enabled dollar-based earnings per share growth despite considerable volatility.
- Emerging Markets Drive Momentum – The company’s exposure to emerging markets continues paying dividends.
- Latin America posted high single-digit organic growth in both Mexico and Brazil during Q4, with strong performance across all three core categories.
- Asia showed sequential improvement with India returning to growth after GST-related challenges.
- The region delivered solid results driven by premiumization strategies, particularly in urban markets, where Colgate is launching premium products such as Total, PerioGard, and Optic White purple variants.
- The company’s Colgate brand remains the most penetrated brand globally, providing a competitive distribution advantage, particularly in emerging markets.
- Hill’s Pet Nutrition Shows Resilience: The Hill’s business delivered exceptional results, with underlying volume growth of 2% excluding the private-label exit.
- The Prescription Diet therapeutic segment continues gaining share across all channels, driven by science-based innovation that resonates with veterinarians and pet owners.
Management expects the wet food production expansion at their Tonganoxie plant to provide greater flexibility for innovation rollouts in 2026, positioning the brand for continued outperformance even as the broader pet category faces softness from reduced adoption rates.
See analysts’ full growth forecasts and estimates for CL stock (It’s free) >>>
What the Model Says for Colgate-Palmolive Stock
We analyzed Colgate-Palmolive as it transitions from its completed 2025 strategy into an ambitious 2030 roadmap focused on five key pillars: leveraging global brand reach, accelerating science-based innovation, implementing omnichannel demand generation, scaling digital capabilities, and strengthening organizational culture.
The company added $5 billion in sales during its previous strategic cycle and now aims to accelerate growth through premiumization and emerging-market penetration.
North America remains a challenge with category volumes declining across nine of the company’s segments in October and ten in November.
However, management sees opportunities through stronger innovation pipelines, easier year-over-year comparisons, and improved execution strategies for 2026.
Using a forecast of 3.7% annual revenue growth and 21.9% operating margins, our model projects the stock will rise to $114 within 2.8 years. This assumes a 23.2x price-to-earnings multiple.
That represents slight compression relative to Colgate’s historical P/E average of 24.6x, reflecting near-term pressures from category softness and competitive promotional activity, particularly in developed markets like the United States.
The real value lies in capturing premiumization opportunities globally while maintaining the core business strength that has sustained the company through decades of market cycles.
Our Valuation Assumptions
Estimate a company’s fair value instantly (Free with TIKR) >>>
Our Valuation Assumptions
TIKR’s Valuation Model lets you plug in your own assumptions for a company’s revenue growth, operating margins, and P/E multiple, and calculates the stock’s expected returns.
Here’s what we used for CL stock:
1. Revenue Growth: 3.7%
Colgate’s growth centers on emerging market expansion and premiumization.
The company delivered organic sales growth above 3% in Q4 when excluding the private label exit, with emerging markets growing at 4.5%.
Management expects category growth to stabilize in the 1.5% to 2.5% range globally, below historical norms but sufficient to support steady expansion when combined with market share gains and premium product introductions.
The 2030 strategy emphasizes investment in strategic growth markets where category dynamics remain more favorable than in developed regions.
2. Operating margins: 21.9%
Colgate maintains operating margins near historical levels around 19.8%-21.9%.
The company continues generating productivity savings through its funding-the-growth initiatives, which delivered strong results in 2025.
The strategic growth and productivity program announced in Q3 should unlock organizational changes and provide funding to invest in brands and capabilities while offsetting cost inflation.
Management sees opportunities for margin expansion through supply chain optimization, predictive analytics, and automation.
3. Exit P/E Multiple: 23.2x
The market currently values Colgate at 24.6x earnings. We assume modest compression to 23.2x over our forecast period.
Category headwinds in North America and competitive promotional pressures create near-term uncertainty.
Foreign exchange has turned favorable after being negative in eight of the past ten years, though management cautioned that this can change quickly.
As the 2030 strategy gains traction and premiumization efforts deliver results, the company should maintain a quality multiple that reflects its global brand strength and consistent cash generation.
Build your own Valuation Model to value any stock (It’s free!) >>>
What Happens If Things Go Better or Worse?
Consumer staples face volatile category dynamics and shifting consumer preferences. Here’s how Colgate stock might perform under different scenarios through December 2030:
- Low Case: If revenue growth slows to 3.1% and net income margins compress to 14.7%, investors still see a 12.9% total return (2.5% annually)
- Mid Case: With 3.4% growth and 15.7% margins, we expect a total return of 37.3% (6.8% annually)
- High Case: If premiumization accelerates, driving 3.7% revenue growth while Colgate maintains 16.4% margins, returns could hit 61.2% total (10.4% annually)
See what analysts think about CL stock right now (Free with TIKR) >>>
The range reflects execution on the omnichannel strategy, successful navigation of promotional environments, and the company’s ability to drive premium innovation across price tiers while defending core market positions.
How Much Upside Does Colgate-Palmolive Stock Have From Here?
With TIKR’s new Valuation Model tool, you can estimate a stock’s potential share price in under a minute.
All it takes is three simple inputs:
- Revenue Growth
- Operating Margins
- Exit P/E Multiple
If you’re not sure what to enter, TIKR automatically fills in each input using analysts’ consensus estimates, giving you a quick, reliable starting point.
From there, TIKR calculates the potential share price and total returns under Bull, Base, and Bear scenarios so you can quickly see whether a stock looks undervalued or overvalued.
See a stock’s true value in under 60 seconds (Free with TIKR) >>>
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
